A study evaluating presence of Uveitis and its association with a sustained response to the Interleukin-1 Inhibitors Anakinra and Canakinumab in behcet's disease
Latest Information Update: 21 Jan 2021
Price :
$35 *
At a glance
- Drugs Anakinra (Primary) ; Canakinumab (Primary)
- Indications Behcet's syndrome
- Focus Therapeutic Use
- 21 Jan 2021 New trial record